Literature DB >> 4004194

Vancomycin disposition during continuous ambulatory peritoneal dialysis: a pharmacokinetic analysis of peritoneal drug transport.

M C Rogge, C A Johnson, S W Zimmerman, P G Welling.   

Abstract

Expressions are presented to describe the absorption and also clearance of drugs administered into the peritoneal cavity of patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Application of the expressions to vancomycin kinetics in five male CAPD patients showed that therapeutic levels of vancomycin can readily be achieved and maintained in the systemic circulation by administering the appropriate loading and maintenance doses. The intrinsic peritoneal clearance of vancomycin reported here is higher than the apparent clearances reported previously, averaging 300 to 500 ml/min under the conditions used in this study. The low apparent clearances previously reported are useful clinically although they do not represent the true efficiency of vancomycin removal by CAPD. The degree to which apparent clearance underestimates the true intrinsic clearance is exponentially related to the dwell time of dialysate in the peritoneum. Intraperitoneal administration is a practical alternative to other routes for CAPD patients needing antibiotic or other therapy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4004194      PMCID: PMC180099          DOI: 10.1128/AAC.27.4.578

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Reduced peritoneal clearances in scleroderma increased by intraperitoneal isoproterenol.

Authors:  S T Brown; D J Ahearn; K D Nolph
Journal:  Ann Intern Med       Date:  1973-06       Impact factor: 25.391

2.  Antibiotic activity in peritoneal dialysate.

Authors:  J Rubin; J Humphries; G Smith; J Bower
Journal:  Am J Kidney Dis       Date:  1983-11       Impact factor: 8.860

3.  Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  R D Blevins; C E Halstenson; N G Salem; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

4.  Stability of antimicrobial agents in peritoneal dialysate.

Authors:  D L Sewell; T A Golper
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

5.  Determinants of low clearances of small solutes during peritoneal dialysis.

Authors:  K D Nolph; R P Popovich; A J Ghods; Z Twardowski
Journal:  Kidney Int       Date:  1978-02       Impact factor: 10.612

6.  Peritoneal transport of vancomycin in 4 patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  S Pancorbo; C Comty
Journal:  Nephron       Date:  1982       Impact factor: 2.847

7.  Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis.

Authors:  P Somani; R S Shapiro; H Stockard; J T Higgins
Journal:  Clin Pharmacol Ther       Date:  1982-07       Impact factor: 6.875

8.  Vancomycin kinetics during continuous ambulatory peritoneal dialysis.

Authors:  C M Bunke; G R Aronoff; M E Brier; R S Sloan; F C Luft
Journal:  Clin Pharmacol Ther       Date:  1983-11       Impact factor: 6.875

9.  Enhancement of peritoneal dialysis clearance with docusate sodium.

Authors:  C B Dunham; L J Hak; J H Hull; A M Mattocks
Journal:  Kidney Int       Date:  1981-11       Impact factor: 10.612

  9 in total
  9 in total

1.  Prediction of serum vancomycin concentrations following intraperitoneal loading doses in continuous ambulatory peritoneal dialysis patients with peritonitis.

Authors:  G R Bailie; G Eisele; R A Venezia; D Yocum; A Hollister
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

Review 2.  Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  E Keller; P Reetze; P Schollmeyer
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

3.  Clearance from dialysate and equilibration of intraperitoneal vancomycin in continuous ambulatory peritoneal dialysis.

Authors:  D Neal; G R Bailie
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

4.  Toxicologic and pharmacokinetic evaluation of a case of vancomycin intoxication during continuous ambulatory peritoneal dialysis.

Authors:  Y A Hekster; T B Vree; C M Weemaes; J J Rotteveel
Journal:  Pharm Weekbl Sci       Date:  1986-12-12

5.  Vancomycin: the tale of the vanquisher and the pyrrhic victory.

Authors:  An S De Vriese; Stefaan J Vandecasteele
Journal:  Perit Dial Int       Date:  2014 Mar-Apr       Impact factor: 1.756

6.  Effect of vancomycin hydrochloride on Staphylococcus epidermidis biofilm associated with silicone elastomer.

Authors:  R C Evans; C J Holmes
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

7.  Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis.

Authors:  G D Morse; D F Farolino; M A Apicella; J J Walshe
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

8.  Cefmenoxime kinetics during continuous ambulatory peritoneal dialysis.

Authors:  D A Sica; R E Polk; T M Kerkering; P Patterson; J Baggett
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Vancomycin Removal During High-Volume Peritoneal Dialysis in Acute Kidney Injury Patients: A Prospective Cohort Clinical Study.

Authors:  Daniela Ponce; Welder Zamoner; Fernanda Moreira Freitas; André Balbi; Linda Awdishu
Journal:  Kidney Int Rep       Date:  2018-09-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.